Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781272 | 0.98 | NPC1 (0.45) | NPC1LMNAALDH1A1THRATHRB | |
| SCHEMBL16060607 | 0.95 | NPC1 (0.38) | NPC1LMNAALDH1A1THRATHRB | |
| SCHEMBL29078783 | 0.91 | — | — | |
| SCHEMBL12561363 | 0.87 | TSHR (0.42) | NPC1LMNAALDH1A1THRATHRB | |
| SCHEMBL26062121 | 0.86 | NPC1 (0.40) | NPC1LMNAALDH1A1THRATHRB | |
| SCHEMBL3861976 | 0.85 | ALDH1A1 (0.44) | NPC1LMNAALDH1A1THRATHRB | |
| SCHEMBL19301645 | 0.83 | LMNA (0.32) | LMNAALDH1A1ALKBH5SUCNR1EGLN1 | |
| SCHEMBL22123617 | 0.83 | TSHR (0.42) | LMNAALDH1A1THRBPTGDR2NAAA | |
| SCHEMBL29114058 | 0.82 | ALDH1A1 (0.47) | NPC1LMNAALDH1A1NAAAEPHX1 | |
| SCHEMBL14343179 | 0.81 | LMNA (0.38) | LMNAALDH1A1ALKBH5SUCNR1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4563146-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-06-04 | — | — | EP | disclosed |
| EP-2970277-B1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2019-01-03 | — | — | US | disclosed |
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| EP-2970277-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Knopp Biosciences LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-104203905-A | Process for producing beta-alkoxypropionamide | IDEMITSU KOSAN CO | 2014-12-10 | — | — | CN | disclosed |
| WO-2014145852-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KCNA7, KCNA2, KCNK17 | NPC1 3849/4885LMNA 2647/4885ALDH1A1 1535/4885 |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | NPC1 3849/4885LMNA 2647/4885ALDH1A1 1535/4885 |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | NPC1 3784/4885LMNA 2739/4885ALDH1A1 1531/4885 |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | NPC1 3849/4885LMNA 2647/4885ALDH1A1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.